Guardant Health Inc
GH: XNAS (USA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
$38.00 | Gtwl | Gqylbpxk |
Guardant Turns in Solid Q3 and Awaits Key Trial Data; No Fair Value Estimate Change
Guardant Health’s third-quarter sales roughly met expectations, but management trimmed its full-year guidance on several likely temporary challenges. We are not changing our $82 fair value estimate and continue to believe that shares in this liquid biopsy player remain undervalued. Our moat and trend ratings remain none and positive, respectively.